To tackle the problem of increasing antibiotic resistance in gram-negative infections, scientists are constantly on the lookout for new drug combinations. Cefepime/enmetazobactam is one such novel β-lactam/β-lactamase inhibitor combination . A recent clinical trial has compared the novel combination with standard piperacillin/tazobactam therapy for complicated urinary tract infections (UTIs) and acute pyelonephritis in 1041 patients.
Group A : Cefepime (2g) and enmetazobactam (0.5g) Group B : Piperacillin (4g) and tazobactam (0.5g) Complete resolution of symptoms and reduction in pathogen (Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, and Enterobacter cloacae) counts (<10 3 CFU/ml in urine) were found more in group A (79.1%) than in group B (58.9%) on day 14. However, both groups reported an increase in alanine aminotransferase, aspartate…
